Literature DB >> 25582278

EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.

Yong Yang1, Yang Yang1, Xiao Zhou1, Xiao Song1, Ming Liu1, Wenxin He1, Hao Wang1, Chunyan Wu2, Ke Fei3, Gening Jiang4.   

Abstract

OBJECTIVES: To retrospectively identify quantitative computed tomographic (CT) features that correlate with the three major driver gene mutations in surgically resected lung adenocarcinomas with dominant ground-glass opacity (GGO) stratified by the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) classification in a Chinese cohort of patients.
MATERIALS AND METHODS: Surgically resected lung adenocarcinomas from Shanghai Pulmonary Hospital were enrolled. EGFR, KRAS and EML4-ALK mutations were detected by qPCR. Clinical and pathological characteristics including gender, age, TNM stage, smoking status and CT pattern were analyzed. Histologic subtype was classified according to IASLC/ATS/ERS classification. At preoperative chest CT, the percentage of GGO volume, diameter, solid volume and total tumor volume of each tumor were measured by using a semiautomated algorithm. Distribution of driver gene mutations was evaluated by using the Fisher exact test, the Student's t test, and Pearson correlation analysis. RESULTS AND
CONCLUSION: 788 in total and 158 GGO tumors were taken in this cohort. GGO pattern occurred at a significantly higher frequency in younger, female and non-smoking patients. EGFR/KRAS mutations and EML4-ALK fusions were similar between GGO and solid adenocarcinomas. GGO volume and diameter showed correlation with EGFR mutation. With regard to association between lung adenocarcinoma histological subtypes and GGO features, GGO proportion was significantly higher in lepidic predominant adenocarcinomas, including adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant invasive adenocarcinoma. No significant differences of driver gene mutations were found between subtypes of lung adenocarcinoma. It is important that we understand GGO lesions of lung adenocarcinoma to identify molecular biomarkers including EGFR, KRAS and EML4-ALK. These markers would offer useful information for determining the appropriate strategy to treat lung adenocarcinoma with GGO lesions detected by helical CT.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25582278     DOI: 10.1016/j.lungcan.2014.12.016

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  36 in total

1.  Correlation in histological subtypes with high resolution computed tomography signatures of early stage lung adenocarcinoma.

Authors:  Yingying Miao; Jianya Zhang; Jiawei Zou; Qingqing Zhu; Tangfeng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

Review 2.  Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.

Authors:  Jian-Wei Gao; Stefania Rizzo; Li-Hong Ma; Xiang-Yu Qiu; Arne Warth; Nobuhiko Seki; Mizue Hasegawa; Jia-Wei Zou; Qian Li; Marco Femia; Tang-Feng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

3.  Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.

Authors:  Su Jin Hong; Tae Jung Kim; Yo Won Choi; Jeong-Soo Park; Jin-Haeng Chung; Kyung Won Lee
Journal:  Eur Radiol       Date:  2016-01-19       Impact factor: 5.315

4.  Semiquantitative Computed Tomography Characteristics for Lung Adenocarcinoma and Their Association With Lung Cancer Survival.

Authors:  Hua Wang; Matthew B Schabath; Ying Liu; Anders E Berglund; Gregory C Bloom; Jongphil Kim; Olya Stringfield; Edward A Eikman; Donald L Klippenstein; John J Heine; Steven A Eschrich; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2015-05-27       Impact factor: 4.785

5.  Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.

Authors:  Etay Ziv; Joseph P Erinjeri; Hooman Yarmohammadi; F Edward Boas; Elena N Petre; Song Gao; Waleed Shady; Constantinos T Sofocleous; David R Jones; Charles M Rudin; Stephen B Solomon
Journal:  Radiology       Date:  2016-07-19       Impact factor: 11.105

6.  Identification of epidermal growth factor receptor mutations in pulmonary adenocarcinoma using dual-energy spectral computed tomography.

Authors:  Meng Li; Li Zhang; Wei Tang; Yu-Jing Jin; Lin-Lin Qi; Ning Wu
Journal:  Eur Radiol       Date:  2018-10-26       Impact factor: 5.315

7.  The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures.

Authors:  Qihua He; Peiling Xin; Mingzhe Zhang; Si Jiang; Jianrong Zhang; Shengyi Zhong; Yang Liu; Minzhang Guo; Xuewei Chen; Xiaojun Xia; Zhenkui Pan; Chenye Guo; Xiuyu Cai; Wenhua Liang; Jianxing He
Journal:  Transl Lung Cancer Res       Date:  2019-04

8.  Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with EGFR and KRAS mutations, and ALK rearrangement: a preliminary study.

Authors:  Meng Li; Li Zhang; Wei Tang; Pei-Qing Ma; Li-Na Zhou; Yu-Jing Jin; Lin-Lin Qi; Ning Wu
Journal:  Transl Lung Cancer Res       Date:  2019-08

9.  Epidermal growth factor receptor mutation accelerates radiographic progression in lung adenocarcinoma presented as a solitary ground-glass opacity.

Authors:  Qijue Lu; Ye Ma; Zhao An; Tiejun Zhao; Zhiyun Xu; Hezhong Chen
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

10.  Multi-channel multi-task deep learning for predicting EGFR and KRAS mutations of non-small cell lung cancer on CT images.

Authors:  Yunyun Dong; Lina Hou; Wenkai Yang; Jiahao Han; Jiawen Wang; Yan Qiang; Juanjuan Zhao; Jiaxin Hou; Kai Song; Yulan Ma; Ntikurako Guy Fernand Kazihise; Yanfen Cui; Xiaotang Yang
Journal:  Quant Imaging Med Surg       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.